Role of platelet in Parkinson’s disease: Insights into pathophysiology &amp; theranostic solutions

Beura, Samir Kumar; Panigrahi, Abhishek; Yadav, Pooja; Singh, Sarita

doi:10.1016/j.arr.2022.101681

Cited by 10 publications

(16 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, platelet structural, functional, and secretory dysfunctions are also confirmed in NDDs, where platelets are observed to ameliorate the disease severity (Figure 1.). 11,12,15,16 2.1 | Role of platelet in AD AD is the most common type of NDD characterized by the deposition of amyloid plaques (containing misfolded Aβ), and neurofibrillary tangles (containing phosphorylated tau/p-Tau) formed extraneuronal and intraneuronal, respectively, resulting in the death of neurons. 17,18 The major clinical symptoms of AD include loss of memory, development of depression, difficulty with language, loss of attentiveness, and extreme apathy affecting around 50 million people globally, and this number is speculated to reach 152 million by 2050.…”

Section: Role Of Platelet In the Pathoprogression Of Nddsmentioning

confidence: 99%

“…27 Although the etiology of PD is conflicting, the frequency of developing cardiovascular complications, especially myocardial infarction, coronary heart disease, congestive heart failure, and ischemic stroke, is significantly high in PD patients. 4,12 Moreover, several classical cardiac determinants raise the risk for atherosclerosis, where thrombus formation is majorly contributed by blood platelet that can regulate the pathoprogression of PD. 28 Platelet alteration is evident in PD, and a recent study revealed that exogenous administration of human α-synuclein could substantially block platelet aggregation by interfering with the thrombin/protease-activated receptor 1 (PAR 1 ) functional axis.…”

Section: Role Of Platelet In Pdmentioning

confidence: 99%

“…Platelet hyperactivation seems to be an important event associated with the majority of the NDDs, for which antiplatelet drugs could be the therapeutic options (Figure 2). 11,12 The following is the list of several synthetic antiplatelet drug candidates showing remarkable evidence of effectiveness in different NDDs.…”

Section: Synthetic Antiplatelet Molecules For Nddsmentioning

confidence: 99%

“…135 Surprisingly, several antiplatelet phytochemicals have been reported that specifically augment neuroprotection by promoting neurotransmitter homeostasis and neuronal growth factor availability and attenuate neurotoxicity by inhibiting oxidative stress and cerebral inflammation in NDDs (Figure 3). 11,12 Here in this section, we will discuss only those phytochemicals with significant antiplatelet and antithrombotic potential that have substantial beneficial effects on the management of NDDs (Table 2).…”

Section: Natural Antiplatelet Compounds For Nddsmentioning

confidence: 99%

See 3 more Smart Citations

Antiplatelet drugs: Potential therapeutic options for the management of neurodegenerative diseases

Beura

Dhapola

Panigrahi

et al. 2023

Medicinal Research Reviews

Self Cite

View full text Add to dashboard Cite

The blood platelet plays an important role but often remains under‐recognized in several vascular complications and associated diseases. Surprisingly, platelet hyperactivity and hyperaggregability have often been considered the critical risk factors for developing vascular dysfunctions in several neurodegenerative diseases (NDDs) like Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. In addition, platelet structural and functional impairments promote prothrombotic and proinflammatory environment that can aggravate the progression of several NDDs. These findings provide the rationale for using antiplatelet agents not only to prevent morbidity but also to reduce mortality caused by NDDs. Therefore, we thoroughly review the evidence supporting the potential pleiotropic effects of several novel classes of synthetic antiplatelet drugs, that is, cyclooxygenase inhibitors, adenosine diphosphate receptor antagonists, protease‐activated receptor blockers, and glycoprotein IIb/IIIa receptor inhibitors in NDDs. Apart from this, the review also emphasizes the recent developments of selected natural antiplatelet phytochemicals belonging to key classes of plant‐based bioactive compounds, including polyphenols, alkaloids, terpenoids, and flavonoids as potential therapeutic candidates in NDDs. We believe that the broad analysis of contemporary strategies and specific approaches for plausible therapeutic treatment for NDDs presented in this review could be helpful for further successful research in this area.

show abstract

Section: Role Of Platelet In the Pathoprogression Of Nddsmentioning

confidence: 99%

Section: Role Of Platelet In Pdmentioning

confidence: 99%

Section: Synthetic Antiplatelet Molecules For Nddsmentioning

confidence: 99%

Section: Natural Antiplatelet Compounds For Nddsmentioning

confidence: 99%

See 2 more Smart Citations

Antiplatelet drugs: Potential therapeutic options for the management of neurodegenerative diseases

Beura

Dhapola

Panigrahi

et al. 2023

Medicinal Research Reviews

Self Cite

View full text Add to dashboard Cite

show abstract

“…The main pathological hallmark of PD is the progressive loss of dopaminergic (DA) neurons in substantia nigra pars compacta (SNpc) with the accumulation of misfolded α-synuclein (α-syn) in the Lewy bodies, which decreases striatal dopamine, and thus leads to motor dysfunction, including bradykinesia and rigidity and/or rest tremors. 1,2 Although the etiology and pathogenesis of PD remains largely unclear, accumulating evidence has indicated that increased oxidative stress, mitochondrial dysfunction, and apoptosis might be key components in the onset and progression of PD. [3][4][5] Post-mortems of brains from PD patients have shown high concentrations of reactive oxygen species (ROS) and mitochondrial respiratory chain complex I deficiency in the SNpc.…”

Section: Introductionmentioning

confidence: 99%

The molecular mechanism of three novel peptides from C-phycocyanin alleviates MPTP-induced Parkinson's disease-like pathology in zebrafish

Xu,

Qiu,

Zhang

et al. 2023

Food Funct.

View full text Add to dashboard Cite

show abstract

Association between 23 drugs and Parkinson's disease: A two‐sample Mendelian randomization study

Xie,

Zhou,

Qiu

et al. 2023

Brain and Behavior

View full text Add to dashboard Cite

BackgroundParkinson's disease (PD) is a common degenerative nervous system disease. At present, there are certain limitations in various treatment options aimed at preventing or delaying the progression of PD. Therefore, the exploration of new drugs for PD is beneficial. Mendelian randomization (MR) analysis can be used to explore the association between drugs and diseases. In this study, MR analysis was adopted to investigate the causal relationship between 23 drugs and PD. These drugs have been approved for the treatment of different diseases, such as salicylic acid and derivatives (collectively called salicylates, e.g., aspirin, used for fever and pain relief), antithrombotic agents (e.g., warfarin, aspirin, used for preventing thrombotic events).MethodsThe GWAS data for the 23 drugs were obtained from the UK Biobank (UKB) project, while the GWAS data for PD were sourced from FinnGen. Single‐Nucleotide Polymorphisms (SNPs) were selected as instrumental variables (IVs). We first performed a series of quality control steps (including MR‐PRESSO) to select the appropriate SNPs. Two‐sample MR analysis was performed using five different methods, including inverse variance weighting (IVW) with random‐effects model, weighted median, MR‐Egger, simple model, and weighted model. At the same time, sensitivity analysis was carried out using the MR‐Egger and Cochran's Q test to ensure the authenticity and reliability of the results.ResultsIn MR‐PRESSO, salicylates and antithrombotic agents showed statistically significant associations with PD, respectively. In the main MR analysis (IVW), there was a negative causal relationship between salicylates and PD (OR = 0.73, 95% CI = 0.54–0.98, p = .039). Similarly, there was a negative causal relationship between antithrombotic agents and PD (OR = 0.70, 95%CI = 0.52–0.96, p = .027). No statistically significant association was found between the remaining 21 drugs and PD.ConclusionThis MR study demonstrated that salicylates and antithrombotic agents can reduce the risk of PD, thus providing a novel avenue for future drug exploration in PD.

show abstract

Role of platelet in Parkinson’s disease: Insights into pathophysiology & theranostic solutions

Cited by 10 publications

References 110 publications

Antiplatelet drugs: Potential therapeutic options for the management of neurodegenerative diseases

Antiplatelet drugs: Potential therapeutic options for the management of neurodegenerative diseases

The molecular mechanism of three novel peptides from C-phycocyanin alleviates MPTP-induced Parkinson's disease-like pathology in zebrafish

Association between 23 drugs and Parkinson's disease: A two‐sample Mendelian randomization study

Contact Info

Product

Resources

About